This Sources Sought opportunity from Department Of Defense was posted on April 25, 2018. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Aluminum Adjuvanted Recombinant Vaccine Drug Product (DP) Formulation Evaluation, DP Process Development and Clinical/Commercial DP Formulation and Filling.

Closed

DVC0600-SS-18Federal

Submission Closed05/09/2018, 09:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541715

New

Federal

U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)

Solicitation # W911PT26SC001

The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) has issued solicitation W911PT26SC001, a Commercial Solutions Opening (CSO) authorized under the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70. This competitive solicitation is open until September 30, 2027, and is designed to acquire innovative commercial products, technologies, and services to modernize the Army's Organic Industrial Base. The scope focuses on integrating manufacturing resources, linking legacy analogue systems with digital systems, and expanding modeling and simulation to enhance the delivery of materiel solutions. The CSO targets both traditional and non-traditional business entities, including small businesses and foreign-owned firms, provided they maintain an active System for Award Management (SAM) profile and a Unique Entity ID. The acquisition process follows a multi-phased approach consisting of a written solution brief, an optional presentation or pitch, and a final Request for Commercial Solution Proposal (CSP). Evaluation is based on responsiveness, technical merit, uniqueness, and price reasonableness. Successful responses may result in fixed-price contracts awarded under FAR Part 12 Commercial Item Procedures. Current Areas of Interest (AoIs) include advanced cannon technology, electrical infrastructure improvements at Building 120, chromium facility conversion, automated manufacturing for minor components, automated cooling tower treatments, advanced CNC vertical turning lathes, and advanced tooling for radial forging. Performance is primarily located at Watervliet Arsenal and Benet Laboratories, with a general period of performance not to exceed 12 months unless otherwise specified.

POSTED

DEADLINE

"Provide specialized piping expertise overseeing the Craft Labor/Corrosion Control subcontractor for field modifications at KSC including but not limited to fabrication and installation of piping spool pieces, piping & tubing supports, flared & welded tub

Solicitation # 80NSSC26945986Q

NASA Shared Services Center

POSTED

DEADLINE

Scientific Data Management and Publication SupportThe Scientific Data Management and Publication Support subcontract, issued by the National Institutes of Health under the Department of Health and Human Services, focuses on the dissemination of data, tools, and technologies for prime contractors involved in NIDCD medical research projects. The selected provider will manage resource sharing between laboratories and the NIDCD, assist in the preparation of scientific publications, and implement NIH Data Management and Sharing plans. These tasks must be executed using statistical software and secure data repositories while maintaining strict adherence to NIH cybersecurity guidelines. The primary deliverables for this engagement include the provision of disseminated data sets and the completion of published research papers. This opportunity falls under NAICS code 541715 and has a response deadline of March 5, 2027.

National Institutes Of Health

POSTED

DEADLINE

Human Temporal Bone and Fresh Ear Tissue Processing LaboratoryThis subcontract for the National Institutes of Health involves the receiving and processing of human temporal bones and fresh ear tissue to support research network projects for the NIDCD. The selected provider will be responsible for obtaining specimens from the National Hearing and Balance Organ Donor Program, processing inner and middle ear tissues, scanning slides, and summarizing donor medical records. Final deliverables include the processed specimens, high-resolution scanned images, and comprehensive annotated data. To execute these tasks, the contractor must possess specialized high-resolution slide scanning equipment and maintain strict biohazard containment protocols. Additionally, the provider is required to maintain an active IRB certification throughout the duration of the project. This effort falls under NAICS code 541715 and is managed under the Department of Health and Human Services.

National Institutes Of Health

POSTED

DEADLINE

Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)

Solicitation # RFA-DC-28-002

Solicitation RFA-DC-28-002 is a Notice of Funding Opportunity from the National Institutes of Health, specifically the National Institute on Deafness and Other Communication Disorders, to establish a Coordinating Center for the NIDCD National Human Ear Resource Network. This collaborative network provides human inner and middle ear tissues to researchers for basic and clinical studies aimed at advancing the treatment of auditory and vestibular disorders. The Coordinating Center is responsible for maintaining network cohesiveness through the planning of workshops, symposia, and regular meetings, providing updates to laboratories, and managing communication with the public and scientific community regarding tissue donation. The maximum project period is five years, with a budget limit of 200,000 dollars in direct costs per year. Applicants, including for-profit organizations and small businesses, must maintain active registrations in SAM, eRA Commons, and Grants.gov. Proposals are evaluated based on the significance of the proposed center and the qualifications of the investigators, with additional reviews for human subject protections, inclusion policies, and the use of vertebrate animals. Key requirements include a structured Data Management and Sharing Plan and adherence to cybersecurity guidelines, including a 48-hour incident reporting window. The application process is entirely electronic and requires several standard PHS and SF424 forms, with a response deadline of March 5, 2027.

National Institutes Of Health

POSTED

DEADLINE

National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)

Solicitation # RFA-DC-28-001

Solicitation RFA-DC-28-001 is a Notice of Funding Opportunity issued by the National Institutes of Health under the Department of Health and Human Services to support the NIDCD National Human Ear Resource Network. The objective is to maintain a collaborative network of laboratories that serve as a national technological resource, providing human inner and middle ear tissues to researchers for basic and clinical studies to advance the treatment of auditory and vestibular disorders. The scope of work includes processing human temporal bones from the National Hearing and Balance Organ Donor Program, uploading images and medical data to EarBase, sharing gene-expression data via the gEAR repository, and providing technical instruction to increase the number of skilled researchers in the field. The NIDCD intends to commit 3.6 million dollars in FY 2028 to fund up to six awards, with a maximum project period of five years. Individual awards are limited to 450,000 dollars in direct costs per year, with an additional 150,000 dollars available for specific subawards. Applications are due on March 05, 2027, and November 01, 2027, with staggered start dates ranging from July 2027 to July 2028. Evaluation is based on the experience of the investigators, the adequacy of the institutional environment, and the protection of human subjects. Applicants must maintain active SAM registration and a Unique Entity Identifier, and they must provide a Data Management and Sharing Plan and a Material Transfer Agreement. Compliance with the Cybersecurity Act of 2015 is required, including the development of an incident response plan and notification of cybersecurity incidents within 48 hours of discovery.

National Institutes Of Health

POSTED

DEADLINE

Silviculture Growth & Yield Modelling SpecialistThe Silviculture Growth and Yield Modelling Specialist subcontract supports prime contractors on projects for the Province of British Columbia's Ministry of Forests. The selected specialist will perform advanced statistical analysis and growth and yield modelling, specifically utilizing the Mixedwood Growth Model to establish stocking standards for conifer, broadleaf, mixedwood, and successional forests. A primary objective of the role is the creation of algorithms designed to project stand attributes based on data gathered from free growing surveys. Candidates must possess advanced proficiency in statistical analysis software and extensive expertise with the Mixedwood Growth Model to successfully deliver the required projection algorithms and modelled results. This opportunity was posted on October 19, 2026, with a response deadline of October 29, 2026.

POSTED

DEADLINE

Mental Health Screening Tool Array DesignThis subcontract, titled Mental Health Screening Tool Array Design, involves providing clinical content and validated screening tools to prime contractors working on Illinois State Board of Education projects. The primary objective is to develop specialized tool arrays capable of identifying childhood mental health challenges related to internalizing, externalizing, and trauma. To ensure clinical efficacy and legal compliance with Public Act 104-0032, the tools must be optimized for administration in under ten minutes. The final deliverable consists of a validated set of screening tools fully integrated into the designated platform. This project is managed under the Community Residential Services Authority for the state of Illinois.

COMRESSERVAUTH586 - Community Residential Services Authority

POSTED

DEADLINE

Notice of Correction to Award Information and Application and Submission Information for PA-27-037 "Predoctoral to Postdoctoral Transition Award (Parent F99/K00 - Clinical Trial Not Allowed)"

Solicitation # NOT-OD-26-091

This notice provides corrections to the award and application information for the Predoctoral to Postdoctoral Transition Award (Parent F99/K00), specifically for solicitation NOT-OD-26-091 issued by the National Institutes of Health. The primary updates involve the removal of Kirschstein-NRSA support period limitations. Eligible individuals may now receive up to five years of aggregate support, consisting of up to two years at the F99 predoctoral level and up to three years at the K00 postdoctoral level. Additionally, the notice clarifies that a Certification Letter is no longer required for these applications, and corresponding instructions have been removed from the SF424(R&R) Other Project Information section. These changes are effective for the application due date of August 8, 2026. For further inquiries, the Division of Biomedical Research Workforce serves as the primary point of contact.

National Institutes Of Health Office Of The Director

POSTED

DEADLINE

Notice of NIBIB Participation in PA-27-037: Predoctoral to Postdoctoral Transition Award (Parent F99/K00 - Clinical Trial Not Allowed)

Solicitation # NOT-EB-26-005

The National Institute of Biomedical Imaging and Bioengineering is joining the Predoctoral to Postdoctoral Transition Award (Parent F99/K00), effective for applications received on or after December 08, 2026. This funding opportunity is designed for researchers transitioning from predoctoral to postdoctoral training, provided that clinical trials are not involved. All submitted applications must align with the specific missions of the participating Institutes and Centers. This update expands the list of participating organizations and agency contacts to include the National Institute of Biomedical Imaging and Bioengineering and its Chief Grants Management Officer. The award is supported by a wide array of National Institutes of Health offices and centers, including the National Cancer Institute and the National Institute on Aging, among others. All other terms and conditions of the original notice of funding opportunity remain unchanged.

National Institute Of Biomedical Imaging And Bioengineering

POSTED

DEADLINE

Notice of FIC Participation in PA-26-002 "NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)"

Solicitation # NOT-TW-26-002

The Fogarty International Center is participating in the NIH Collaborative International Research Project, identified as PA-26-002. This funding opportunity is effective for applications submitted on or after January 25, 2027. The program is designed for collaborative international research projects and allows for optional clinical trials. A wide array of NIH Institutes and Centers are participating organizations, and applications must align with their specific missions. Additionally, the Office of Research on Women's Health, the INCLUDE Project, and the Office of Data Science Strategy may provide co-funding for assigned applications. All other terms and conditions of the original notice of funding opportunity remain unchanged.

POSTED

DEADLINE

Thermal Performance & Dielectric Testing LaboratoryThis subcontract opportunity is for a Thermal Performance and Dielectric Testing Laboratory to provide independent testing and validation services for prime contractors supporting USAF AFLCMC/WAR F-22 cooling fluid projects. The selected provider will be responsible for evaluating low-temperature viscosity, high-temperature stability, and dielectric strength utilizing specialized equipment such as viscosity meters and stability chambers. The final deliverables for this engagement include comprehensive technical test reports and performance validation data. To be eligible, the contractor must be a domestic U.S. company and hold ISO/IEC 17025 accreditation. The work is associated with NAICS code 541715 and will be performed at Wright Patterson AFB. Interested parties must submit their responses by November 3, 2026.

FA8611 Aflcmc Wauk F22

POSTED

1 day ago

DEADLINE

in 14 days

General Info

Agency

Department Of Defense → W6QK Acc-Apg Natick

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

110 Thomas Johnson Drive, FREDERICK, MD, 21702, USA

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed

PostedApr 25

Sources Sought

Response DeadlineMay 9

Deadline has passed

Submission Closed

05/09/2018, 09:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → W6QK Acc-Apg Natick

Contacts2 people available

OfficeNATICK, MA, 01760-5011, USA

Organization / AgencyDepartment Of Defense → W6QK Acc-Apg Natick

Office AddressNATICK, MA, 01760-5011, USA

Contacts

Alesha SubasicDVC

contact@example.gov

Jessica L. Ely

contact@example.gov

+1 (555) 000-0000

Full Description

DynPort Vaccine Company LLC, a General Dynamics Information Technology Company (DVC), a biopharmaceutical company in Frederick, Maryland, is issuing this Request for Information (RFI) to gain insight into the capabilities of potential industry partners in aluminum adjuvanted recombinant vaccine drug product (DP) formulation evaluation, DP process development and clinical/commercial cGMP DP manufacturing. These efforts will involve evaluating the current DP formulation, and investigating potential formulation/manufacturing process changes/improvements. Additionally, task may include incorporating the recommended procedures into the clinical/commercial DP formulation and filling manufacturing operations. Finally, responses should consider potential regulatory challenges based on proposed formulation and/or process changes. Note that it is possible that a vendor may not have expertise in all areas of this RFI, however vendors should provide information in the areas that can be supported. Information gathered at this time will help guide DVC in structuring the future potential Request For Proposal (RFP). This RFI announcement is for information purposes only; it is not to be construed as an obligation on the part of DVC. In order to proactively plan for future requirements, DVC is conducting market research to locate qualified, experienced, and interested large and small businesses to assess qualified, and experienced interested sources. No contract will be awarded from this announcement. No reimbursement will be made for any cost associated with providing information in response to this announcement. Please provide your capabilities statement for the following Task Areas, noting that any or all of the work scope may ultimately move forward. Responses shall include past performance for same or similar work performed. Background: The vaccine in the current DP formulation has been tested in nonclinical safety and efficacy studies. Phase 1 and Phase 2 clinical trials have been completed. Instructions Vendors should respond to one or more of the Task Areas for which they have applicable expertise. For each Task Area to which a vendor responds, please include the following information along with specific responses to the task area questions: - Provide a description of your facility and manufacturing capabilities. - Describe physiochemical analytical capabilities for characterization of an aluminum adjuvanted recombinant vaccine (i.e. purity, protein concentration, particulate identification, aluminum content, etc.) or comparable liquid suspension product. - Provide the qualifications of technical staff with demonstrated experience. - Describe relevant capabilities in Quality Systems, Regulatory Affairs and Support. Task Area A - Formulation Evaluation and Optimization 1. What scientific approaches would the offeror recommend to evaluate the optimal formulation of an aluminum adjuvanted recombinant vaccine DP formulation? 2. Describe current and previous experience with formulation development of aluminum adjuvanted vaccines or comparable liquid suspension products. Experience with specific adjuvants and vaccines should be detailed. 3. Describe current and previous experience with compounding and aseptic filling of clinical/commercial liquid suspension product into vials. 4. Describe physiochemical analytical capabilities for characterization of an aluminum adjuvanted recombinant vaccine (i.e. purity, protein concentration, particulates, aluminum content, etc.). Task Area B - Process Development 1. What technical approaches and methods would be used to ultimately develop a commercial process that could be used to manufacture an aluminum adjuvanted recombinant vaccine DP according to cGMP requirements? 2. Describe current and previous experience with manufacturing process development. 3. Describe experience with development of clinical manufacturing processes that were successfully transitioned to commercial manufacturing. 4. Provide a description of analytical capabilities available for DP Critical Quality Attribute (CQA) analysis (i.e. strength, purity, identity, etc.). Task Area C - Clinical/Commercial DP Manufacturing 1. Provide a description of the cGMP manufacturing capabilities of your facility, including number of clinical and commercial products being manufactured, and a description of quality systems. 2. Describe current and previous experience with manufacturing of aluminum adjuvanted and/or liquid suspension products. 3. Provide cGMP manufacturing experience including experience with transitioning products from clinical to commercial stage. 4. Describe production design in regards to flexibility and operating capacity targeting 30,000 to 100,000 unit lot size. 5. Describe how your facility addresses trends and challenges within industry, particularly as related to visual inspection of parenteral products (i.e. elimination of subjectivity in the visual inspection process, addition/changes to the USP guidance on visual inspection, etc.) 6. Provide a description of analytical capabilities available for DP CQA analysis (i.e. strength, purity, identity, etc.). Additional Required Information The following information shall be provided: 1. DUNS and CAGE Code Number 2. Tax ID Number 3. Company name and address 4. Principal Point of Contact, phone number and email (both technical and administrative/business) 5. NAICS codes associated with this capability 6. Company size (i.e. small business, 8(a), veteran owned, etc) Contact Information: All responses to this RFI shall be submitted no later than Wednesday, 9 May 2018 4:00 PM, Eastern Standard Time (EST) via email to Alesha.Subasic@CSRA.com. Disclaimer: This notice does not obligate DVC to award a contract or otherwise pay for the information provided in response. Note that DVC will not entertain questions regarding this Market Research; however, general questions can be presented in your response. Confidentiality: No proprietary, classified, confidential or sensitive information should be included in your response.